Recent Updates
Recently added Catalysts
VYGR Positive Sentiment

Voyager to Present at Upcoming Investor Conferences

Key Takeaway: Voyager Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the 2026 Cantor Global Healthcare Conference. The company aims to highlight its innovative approaches to treating neurological diseases. A webcast of the Wells Fargo fireside chat will be available for investors.
Price reaction · baseline $3.45 (2026-08-31 close) · hit pre-market · clean, no other VYGR news in the window
day 0 close
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Voyager Therapeutics is actively engaging with investors through multiple conferences.
  • The company showcases its commitment to neurological disease treatment advancements.
  • Webcasts of presentations enhance accessibility for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+2%
120-day peak, hindsight
Typical move
2.4%
average across 4 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
VY7523
Phase 1 · Alzheimer's Disease (AD)

Full Press Release Details

LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:
• Wells Fargo 21st Annual Healthcare Conference: Fireside chat at 3:45 p.m. ET on Tuesday, September 8, 2026, in Boston, MA.
• 2026 Cantor Global Healthcare Conference: Fireside chat at 8:35 a.m. ET on Friday, September 11, 2026, in New York, NY.
• Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat at 10:45 a.m. ET on Monday, September 14, 2026, in New York, NY.
• Baird’s 2026 Global Healthcare Conference: Fireside chat at 7:55 a.m. ET on Tuesday, September 15, 2026, in New York, NY.
• H.C. Wainwright 28th Annual Global Investment Conference: Fireside chat at 2:30 p.m. ET on Tuesday, September 15, 2026, in New York, NY.
A webcast of the Wells Fargo fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the company’s website for at least 30 days.
About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.
Voyager Therapeutics ® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Contacts Company and Investors: Trista Morrison, NACD.DC, tmorrison@vygr.com Media: Lisa Guiterman, voyagerpr@scientpr.com

Frequently Asked Questions

When is Voyager's presentation at the Wells Fargo Conference?

Voyager will present at the Wells Fargo Conference on September 8, 2026.

What is the focus of Voyager Therapeutics?

Voyager Therapeutics focuses on leveraging genetics to treat neurological diseases.

Where can I access the webcast of Voyager's presentations?

The webcast will be available on Voyager's investor website.

Which diseases does Voyager's pipeline target?

Voyager's pipeline includes Alzheimer's, Parkinson's, ALS, and more.

Last updated: Sep 1, 2026